Semaglutide typical research dosing
Across the available literature, Semaglutide is most commonly administered at 250–2400 mcg per dose, 1 time(s) per day, via subcutaneous injection. Clinical protocols escalate from 0.25 mg weekly to 2.4 mg weekly over 16 weeks to minimize gastrointestinal side effects.
Semaglutide unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 5 mg Semaglutide vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 250 mcg | 1325 mcg | 2400 mcg |
|---|---|---|---|---|
| 1 mL | 5000 mcg/mL | 5.0 units | 26.5 units | 48.0 units |
| 2 mL | 2500 mcg/mL | 10.0 units | 53.0 units | 96.0 units |
| 3 mL | 1667 mcg/mL | 15.0 units | 79.5 units | 144.0 units |
| 5 mL | 1000 mcg/mL | 25.0 units | 132.5 units | 240.0 units |
Semaglutide cycle length
Most reported Semaglutide protocols run 16 weeks on, then 0 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
Semaglutide half-life and timing
Semaglutide has a half-life of approximately 168 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.